Delivery Order SPE2DB22D1017-SPE2DB25FYRBU
- Not listed
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,194.80 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed-price contract. The award, issued on September 19, 2025, with an ultimate completion date of September 22, 2025, represents a competitively awarded non-set-aside procurement. Performance of this delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,585.72 for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed price contract. This non-set-aside award was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded a $1,883.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/ML vials (10 mL) with an ultimate completion date of September 30, 2025. This non-set-aside award was issued on September 29, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10 mL) with a firm fixed price of $3,831.58. The contract was competitively awarded without set-asides and carries an ultimate completion date of September 9, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The Defense Logistics Agency awarded a $1,023.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10 mL) on July 14, 2025, with an ultimate completion date of July 15, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,300.68 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL pens (3mL) under a firm fixed price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a non-set-aside, competitively awarded transaction and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) valued at $2,843.25 on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, firm fixed price delivery order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYRBUDelivery Order
The Defense Logistics Agency awarded a $1,692.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) with a completion date of September 18, 2025. This non-set-aside delivery order was competitively awarded and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply a broad range of medications and medical commodities to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates its role as a critical vendor for military and veteran healthcare systems, supplying specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The award reflects DLA's ongoing procurement strategy to maintain reliable pharmaceutical supply chains for Department of Defense medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/17/25 |